Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 4NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 4

Conditions

Carcinoma, Non-Small-Cell Lung 926Neoplasms 609Breast Neoplasms 604Colorectal Neoplasms 457Neoplasm Metastasis 394Ovarian Neoplasms 328Melanoma 312Prostatic Neoplasms 311Lung Neoplasms 294Multiple Myeloma 290Recurrence 278Squamous Cell Carcinoma of Head and Neck 246Stomach Neoplasms 229Pancreatic Neoplasms 228Leukemia, Myeloid, Acute 220Triple Negative Breast Neoplasms 190Endometrial Neoplasms 190Carcinoma, Renal Cell 182Lymphoma, Non-Hodgkin 179Carcinoma, Hepatocellular 177Small Cell Lung Carcinoma 165Leukemia, Lymphocytic, Chronic, B-Cell 156Advanced Solid Tumors 154Lymphoma, Follicular 148Urinary Bladder Neoplasms 139Lymphoma, Large B-Cell, Diffuse 138Lymphoma 137Advanced Solid Tumor 137Uterine Cervical Neoplasms 134Head and Neck Neoplasms 134

Interventions

relacorilant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Pituitary ACTH Hypersecretion × 1 year × Clear all
NCT05804669 2026-06-04

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Crinetics Pharmaceuticals Inc.

Phase 1/2 Recruiting
18 enrolled
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Pituitary ACTH Hypersecretion

NCT03604198 2026-04-21

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Corcept Therapeutics

Phase 2 Active not recruiting
125 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion

NCT05307328 2025-10-08

RESCUE

Sparrow Pharmaceuticals

Phase 2 Completed
26 enrolled
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Pituitary ACTH Hypersecretion

NCT03697109 2025-07-16

GRACE

Corcept Therapeutics

Phase 3 Completed
152 enrolled 28 charts
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡